Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Author [ Title] Type Year Filters: Author is Athyros, Vasilios G [Clear All Filters]
High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice..
J Diabetes Complications. 30(1), 9-11.
(2016). High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus..
J Diabetes Complications. 29(1), 142-5.
(2015). Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?.
Curr Vasc Pharmacol. 9(6), 698-705.
(2011). Hyperuricemia as a risk factor for cardiovascular disease..
Expert Rev Cardiovasc Ther. 13(1), 19-20.
(2015). Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels..
Curr Drug Targets. 8(3), 483-8.
(2007). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy..
Expert Opin Pharmacother. 11(5), 723-30.
(2010). The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study..
Curr Vasc Pharmacol. 11(5), 779-84.
(2013). Impact of statins on glucose metabolism--a matter of debate..
Am J Cardiol. 107(12), 1866.
(2011). Implementation of guidelines for the management of arterial hypertension. The impulsion study..
Open Cardiovasc Med J. 3, 26-34.
(2009).
(2011). JUPITER: major implications for vascular risk assessment..
Curr Med Res Opin. 25(1), 133-7.
(2009).
(2009). Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study..
Diabetes Care. 26(7), 1955-60.
(2003). Lipid lowering agents and the endothelium: an update after 4 years..
Curr Vasc Pharmacol. 10(1), 33-41.
(2012). Lipid-lowering agents and new onset diabetes mellitus..
Expert Opin Pharmacother. 11(12), 1965-70.
(2010). Lipoprotein a: where are we now?.
Curr Opin Cardiol. 24(4), 351-7.
(2009). Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases..
J Crohns Colitis. 8(9), 936-44.
(2014).
(2021). Management of statin-intolerant high-risk patients..
Curr Vasc Pharmacol. 8(5), 632-7.
(2010). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease..
Dig Dis Sci. 57(4), 1109.
(2012). Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008). Metabolic syndrome and arterial stiffness: the past, the present and the future..
J Cardiovasc Med (Hagerstown). 14(10), 687-9.
(2013). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Metabolic syndrome in clinical practice..
Cardiol J. 21(2), 209.
(2014).